- Graduate School - University of Texas Health Science Center at Dallas (2001-2004), Public Health
- Other Post Graduate Training - University of Texas Health Science Center at Dallas (2001-2004)
- Fellowship - UT Southwestern Medical Center (1999-2002), Infectious Diseases
- Residency - Baylor College of Medicine (1996-1999), Internal Medicine
- Medical School - Baylor College of Medicine (1992-1996)
Mamta Jain, M.D.
- Internal Medicine - Infectious Diseases and Geographic Medicine
- Hepatitis C
Mamta K. Jain, M.D., M.P.H., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center. She specializes in infectious diseases and conducts clinical trials to evaluate new therapies for HIV, hepatitis C, influenza, and now COVID-19.
Dr. Jain earned her medical degree at Baylor College of Medicine. She completed a residency in internal medicine at Baylor Affiliated Hospitals and received advanced training in infectious diseases through a fellowship at UT Southwestern. She also holds a Master of Public Health degree with a focus on epidemiology and statistics from the University of Texas Houston School of Public Health – Dallas branch.
Certified by the American Board of Internal Medicine in infectious diseases, she joined the UT Southwestern faculty in 2002.
During the COVID-19 pandemic, Dr. Jain has been at the forefront of conducting clinical trials to find effective therapies for the disease. Her investigations have brought access to novel therapies for more than 100 COVID-19 patients at UT Southwestern and Parkland Memorial Hospital.
Dr. Jain’s research is also aimed at improving clinical outcomes for patients with HIV and viral hepatitis, and she has received significant grant support for her work. She has delivered scores of international, national, and regional invited lectures, contributed to the book HIV and Liver Disease, and published a number of academic articles.
She is a Fellow of the Infectious Diseases Society of America (IDSA) and is on the Board of Directors for the HIV Medicine Association. She is also a member of the IDSA Guidelines Committee for Infection Prevention for COVID-19.
- Infectious Diseases Society of America
- American Association for the Study of Liver Diseases
- American College of Physicians
- Texas Medical Association
- Mid-Career Women Faculty Professional Development Seminar 2014, Nominated by Department Chair to Attend Seminar offered by Association of American Medical Colleges
- Best Doctors in Dallas 2011, D Magazine
- Travel Award 2007, American Society for Clinical Investigation/Association of American Physicians Joint Meeting
- Travel Award 2001, Infectious Diseases Society of America
Acute and chronic viral hepatitis in Conn’s Current Therapy 2008. Ed. Robert Rakel and Edward Bope
Jain MK and Brailita DM (2008), Philadelphia, Saunders/Elsevier
Treatment of hepatitis B in HIV-infected persons in HIV and Liver Disease 1st edition. Ed. Kenneth Sherman
Kitchell E and Jain MK (2012), New York, Springer
- Acute and chronic viral hepatitis in Conn’s Current Therapy 2008. Ed. Robert Rakel and Edward Bope
A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy.
Yuan H, Adams-Huet B, Petersen T, Attar N, Lee WM, Jain MK Journal of medical virology 2012 Dec 84 12 1913-9
Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial.
Metsch LR, Feaster DJ, Gooden L, Matheson T, Stitzer M, Das M, Jain MK, Rodriguez AE, Armstrong WS, Lucas GM, Nijhawan AE, Drainoni ML, Herrera P, Vergara-Rodriguez P, Jacobson JM, Mugavero MJ, Sullivan M, Daar ES, McMahon DK, Ferris DC, Lindblad R, VanVeldhuisen P, Oden N, Castellón PC, Tross S, Haynes LF, Douaihy A, Sorensen JL, Metzger DS, Mandler RN, Colfax GN, del Rio C JAMA 2016 Jul 316 2 156-70
Hepatitis B virus genotype G: Prevalence and impact in patients co-infected with human immunodeficiency virus.
Dao DY, Balko J, Attar N, Neak E, Yuan HJ, Lee WM, Jain MK Journal of medical virology 2011 Sep 83 9 1551-8
Host-based ribavirin resistance influences hepatitis C virus replication and treatment response.
Ibarra KD, Jain MK, Pfeiffer JK Journal of virology 2011 Jul 85 14 7273-83
Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*.
Yuan HJ, Jain M, Snow KK, Gale M, Lee WM Journal of viral hepatitis 2010 Mar 17 3 208-16
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.
Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, Trikha A, Sherman M, Sulkowski MS, Dieterich DT, Rigsby MO, Wright TL, Hernandez MD, Jain MK, Khatri GK, Sterling RK, Bonacini M, Martyn CA, Aytaman A, Llovet JM, Brown ST, Bini EJ Journal of hepatology 2007 Oct 47 4 527-37
Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy?
Jain MK, Opio CK, Osuagwu CC, Pillai R, Keiser P, Lee WM Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007 Apr 44 7 996-1000
Has Access to HCV Therapy Changed for Patients with Mental Health or Substance Use Disorders in the DAA Period?
Jain MK, Thamer M, Therapondos G, Shiffman ML, Kshirsagar O, Clark C, Wong RJ Hepatology (Baltimore, Md.) 2018 Jul
Prospective longitudinal substance use patterns in patients preparing for hepatitis C treatment.
North CS, Pollio DE, Sims OT, Jain MK, Hong BA Journal of dual diagnosis 2017 Oct 0
Clinical and Sociobehavioral Prediction Model of 30-Day Hospital Readmissions Among People With HIV and Substance Use Disorder: Beyond Electronic Health Record Data.
Nijhawan AE, Metsch LR, Zhang S, Feaster DJ, Gooden L, Jain MK, Walker R, Huffaker S, Mugavero MJ, Jacobs P, Armstrong WS, Daar ES, Sullivan M, Del Rio C, Halm EA Journal of acquired immune deficiency syndromes (1999) 2019 Mar 80 3 330-341
Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study.
Pinato DJ, Allara E, Chen TY, Trevisani F, Minguez B, Zoli M, Harris M, Dalla Pria A, Merchante N, Platt H, Jain M, Caturelli E, Kikuchi L, Pineda J, Nelson M, Farinati F, Rapaccini GL, Aytaman A, Yin M, Tan CK, Bower M, Giannini EG, Bräu N Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Feb 37 4 296-304
Evaluation of a multifaceted intervention to reduce health disparities in hepatitis C screening: a pre-post analysis.
Jain MK, Rich NE, Ahn C, Turner BJ, Sanders JM, Adamson B, Quirk L, Perryman P, Santini NO, Singal AG, Hepatology (Baltimore, Md.) 2019 Apr
Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study.
Sterling RK, Wahed AS, King WC, Kleiner DE, Khalili M, Sulkowski M, Chung RT, Jain MK, Lisker-Melman M, Wong DK, Ghany MG The American journal of gastroenterology 2018 Nov
Significant Increase in Risk of Fibrosis or Cirrhosis at Time of HCV Diagnosis for Hispanics With Diabetes and Obesity Compared With Other Ethnic Groups.
Turner BJ, Wang CP, Melhado TV, Bobadilla R, Jain MK, Singal AG Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2018 Dec
The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma.
Pinato DJ, Sharma R, Citti C, Platt H, Ventura-Cots M, Allara E, Chen TY, Dalla Pria A, Jain M, Mínguez B, Kikuchi L, Kaufman West E, Merli M, Kaplan DE, Hasson H, Marks K, Nelson M, Núñez M, Aytaman A, Bower M, Bräu N Alimentary pharmacology & therapeutics 2017 Oct
Signature molecules expressed differentially in a liver disease stage-specific manner by HIV-1 and HCV co-infection.
Whitmill A, Kim S, Rojas V, Gulraiz F, Afreen K, Jain M, Singh M, Park IW PloS one 2018 13 8 e0202524
Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study.
Yek C, de la Flor C, Marshall J, Zoellner C, Thompson G, Quirk L, Mayorga C, Turner BJ, Singal AG, Jain MK BMC medicine 2017 Nov 15 1 204
Missed Initial Medical Visits: Predictors, Timing, and Implications for Retention in HIV Care.
Nijhawan AE, Liang Y, Vysyaraju K, Muñoz J, Ketchum N, Saber J, Buchberg M, Venegas Y, Bullock D, Jain MK, Villarreal R, Taylor BS AIDS patient care and STDs 2017 May 31 5 213-221
Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization.
Peterson RL, Vock DM, Powers JH, Emery S, Cruz EF, Hunsberger S, Jain MK, Pett S, Neaton JD Clinical trials (London, England) 2017 Mar 1740774517697919
An effectiveness study of group psychoeducation for hepatitis C patients in community clinics.
North CS, Pollio DE, Sims OT, Jain MK, Brown GR, Downs DL, Lisker-Melman M, Hong BA European journal of gastroenterology & hepatology 2017 Feb
An assessment of concurrent drug and alcohol use among patients seeking treatment for hepatitis C.
Sims OT, Pollio DE, Hong BA, Jain MK, Brown GR, North CS Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 2016 Feb 28 1 31-6
Faldaprevir and pegylated interferon a-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Dieterich D, Nelson M, Soriano V, Arastéh K, Guardiola JM, Rockstroh JK, Bhagani S, Laguno M, Tural C, Ingiliz P, Jain MK, Stern JO, Manero M, Vinisko R, Kort J AIDS (London, England) 2015 Mar 29 5 571-81
Health Beliefs and Co-morbidities Associated with Appointment-Keeping Behavior Among HCV and HIV/HCV Patients.
Pundhir P, North CS, Fatunde O, Jain MK Journal of community health 2015 Jul
Half of 30-Day Hospital Readmissions Among HIV-Infected Patients Are Potentially Preventable.
Nijhawan AE, Kitchell E, Etherton SS, Duarte P, Halm EA, Jain MK AIDS patient care and STDs 2015 Jul
Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Baker J, Engen N, Huppler Hullsiek K, Stephan C, Jain M, Munderi P, Pett S, Duprez D HIV medicine 2015 Apr 16 Suppl 1 109-18
Micro-RNA-122 levels in acute liver failure and chronic hepatitis C.
Dubin PH, Yuan H, Devine RK, Hynan LS, Jain MK, Lee WM Journal of medical virology 2014 Jun
Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.
Jain MK, Adams-Huet B, Terekhova D, Kushner LE, Bedimo R, Li X, Holodniy M Journal of viral hepatitis 2014 Feb
Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults.
Chen EY, North CS, Fatunde O, Bernstein I, Salari S, Day B, Jain MK Journal of viral hepatitis 2013 Oct 20 10 708-14
Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection.
Jain MK, Pasipanodya JG, Alder L, Lee WM, Gumbo T Antimicrobial agents and chemotherapy 2013 Mar 57 3 1115-20
Patient perspectives on hepatitis C and its treatment.
North CS, Devereaux R, Pollio DE, Hong BA, Jain MK European journal of gastroenterology & hepatology 2013 Jun
Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, Mauss S, Núñez M, Nüesch R, Peters M, Reiberger T, Stephan C, Tan L, Gilson R PloS one 2013 8 7 e68152
Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection.
Yopp AC, Subramanian M, Jain MK, Mansour JC, Schwarz RE, Balch GC, Singal AG Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2012 Nov 10 11 1284-90
Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis.
Jain MK, Seremba E, Bhore R, Dao D, Joshi R, Attar N, Yuan HJ, Lee WM AIDS patient care and STDs 2012 Feb 26 2 73-80
Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment.
Jain MK, Yuan HJ, Adams-Huet B, Reeck A, Shelton J, Attar N, Zhang S, Neumann AU, Carney DS, Gale M, Lee WM The Journal of infectious diseases 2009 Sep 200 6 866-76
Gamma/Delta T cell mRNA levels decrease at mucosal sites and increase at lymphoid sites following an oral SIV infection of macaques.
Kosub DA, Durudas A, Lehrman G, Milush JM, Cano CA, Jain MK, Sodora DL Current HIV research 2008 Nov 6 6 520-30
Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors.
Jain MK, Aragaki C, Fischbach L, Gibson S, Arora R, May L, Vardhineni K, Lee WM HIV medicine 2007 Nov 8 8 491-7
Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM Journal of viral hepatitis 2007 Mar 14 3 176-82
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115.
Riddler SA, Jiang H, Tenorio A, Huang H, Kuritzkes DR, Acosta EP, Landay A, Bastow B, Haas DW, Tashima KT, Jain MK, Deeks SG, Bartlett JA, Antiviral therapy 2007 12 4 531-41
Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000.
Jain MK, Skiest DJ, Cloud JW, Jain CL, Burns D, Berggren RE Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003 Apr 36 8 1030-8
Evaluating non-invasive markers to identify advanced fibrosis by liver biopsy in HBV/HIV coinfected adults.
Sterling RK, King WC, Wahed AS, Kleiner DE, Khalili M, Sulkowski M, Chung RT, Jain MK, Lisker-Melman M, Wong DK, Ghany MG, Hepatology (Baltimore, Md.) 2019 Jun
Immediate antiretroviral therapy reduces risk of infection-related cancer during early HIV infection.
Borges ÁH, Neuhaus J, Babiker AG, Henry K, Jain MK, Palfreeman A, Mugyenyi P, Domingo P, Hoffmann C, Read TR, Pujari S, Meulbroek M, Johnson M, Wilkin T, Mitsuyasu R Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 Sep
Gamma/Delta T-cell functional responses differ after pathogenic human immunodeficiency virus and nonpathogenic simian immunodeficiency virus infections.
Kosub DA, Lehrman G, Milush JM, Zhou D, Chacko E, Leone A, Gordon S, Silvestri G, Else JG, Keiser P, Jain MK, Sodora DL, Journal of virology 2008 Feb 82 3 1155-65
Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment.
Wong RJ, Jain MK, Therapondos G, Shiffman ML, Kshirsagar O, Clark C, Thamer M The American journal of gastroenterology 2018 Mar
The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health.
Bedimo RJ, Drechsler H, Jain M, Cutrell J, Zhang S, Li X, Farukhi I, Castanon R, Tebas P, Maalouf NM PloS one 2014 9 8 e106221
Gonoccocal Retropharyngeal Abscess Complicated by Cervical Osteomyelitis in a Patient with Acquired Immunodeficiency Syndrome
Reddy S, Jain M, Horan K, Skiest D, Gander R Infectious Diseases in Clinical Practice 2001 10 275-278
Access by English and Non-English Speakers Is Needed to COVID-19Â Clinical Trials.
Jain MK, Rollins N, Jain R, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020 Apr
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Huhn GD, Ramgopal M, Jain MK, Hinestrosa F, Asmuth DM, Slim J, Goldstein D, Applin S, Ryu JH, Jiang S, Cox S, Das M, Nguyen-Cleary T, Piontkowsky D, Guyer B, Rossaro L, Haubrich RH, PloS one 2020 15 1 e0224875
Predictors for Poor Linkage to Care Among Hospitalized Persons Living with HIV and Co-Occurring Substance Use Disorder.
Summers N, Colasanti J, Feaster D, Armstrong W, Rodriguez A, Jain M, Jacobs P, Metsch L, Del Rio C, AIDS research and human retroviruses 2020 Jan
Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial.
Ghazi L, Baker JV, Sharma S, Jain MK, Palfreeman A, Necsoi C, Murray DD, Neaton JD, Drawz PE, American journal of hypertension 2020 Jan 33 1 43-52
Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment.
Wong RJ, Jain MK, Therapondos G, Shiffman ML, Kshirsagar O, Clark C, Thamer M, Journal of clinical and experimental hepatology 2020 Mar-Apr 10 2 114-123
Patient and Provider-Level Barriers to Hepatitis C Screening and Linkage to Care: A Mixed-Methods Evaluation.
Higashi RT, Jain MK, Quirk L, Rich NE, Waljee AK, Turner BJ, Lee SC, Singal AG, Journal of viral hepatitis 2020 Feb
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
Davey RT, Fernández-Cruz E, Markowitz N, Pett S, Babiker AG, Wentworth D, Khurana S, Engen N, Gordin F, Jain MK, Kan V, Polizzotto MN, Riska P, Ruxrungtham K, Temesgen Z, Lundgren J, Beigel JH, Lane HC, Neaton JD, The Lancet. Respiratory medicine 2019 Nov 7 11 951-963
- A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy.
- HIV/HCV Co-Infection
- HIV/HBV Co-Infection
- HIV Related Mortality
- Influenza Therapeutics
- Hepatitis C
- Hepatitis B